Experiencing food insecurity in early childhood is associated with worse heart health two decades later, especially higher Body Mass Index (BMI). But participation in the Supplemental Nutrition Assistance Program (SNAP) may significantly mitigate that risk, reports a long-term Northwestern Medicine study published in JAMA Cardiology.
A new study published in Aging Cell demonstrates that artificial intelligence can be used not just to accelerate drug discovery, but to fundamentally transform how it’s done—by targeting the full complexity of biological aging.
A low FODMAP diet developed by Monash University researchers for irritable bowel syndrome (IBS) has been shown to improve gastrointestinal symptoms in women with endometriosis.
In a new study published in Nature, researchers at the University of Chicago Medicine Comprehensive Cancer Center explore a surprising phenomenon in which high doses of radiation cause growth in existing metastatic tumors that weren’t directly treated with radiation.
A group of researchers has developed a new formulation for the only drug available on the market to treat helminths, as worms such as schistosomes and tapeworms are known. According to the World Health Organization (WHO), 400 million people worldwide suffer from these worms.
New research by ESMT Berlin and the Halle Institute for Economic Research (IWH) shows that private equity (PE) acquisitions lead to substantial operational efficiency gains in hospitals, challenging common public concerns. The study reveals that hospitals acquired by PE firms significantly reduce costs and administrative staff without increasing closure rates or harming patient care.
Immunotherapy uses a person’s own immune system to fight cancer. Immune checkpoint inhibitors are one class of immunotherapy that block specific proteins from slowing the immune response. As a result, immune cells become more active and can more effectively kill cancer cells. However, most patients either respond poorly to checkpoint inhibitors or eventually become resistant to the treatment.
A transient ischemic attack, also known as a mini-stroke, is typically defined as a temporary blockage of blood flow to the brain that causes symptoms that go away within a day, but a new study finds that people who have this type of stroke may also have prolonged fatigue lasting up to one year.
To help neurologists, clinicians and families understand the current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec, the American Academy of Neurology (AAN) has issued an Evidence in Focus article in Neurology.